Cancer peptides are short amino acid sequences widely used in oncology research to develop targeted diagnostic and therapeutic approaches. They can bind to tumor-associated receptors, interact with cellular membranes, or interfere with the tumor microenvironment. Depending on the application, these mechanisms support research into specific delivery, tumor imaging, and tumor cell targeting while aiming to reduce unwanted on healthy tissue. RGD peptides form a key group that targets integrin receptors involved in angiogenesis and tumor progression. Non-RGD variants focus on tumor homing, cell penetration, and immune modulation.
For research use only. JPT’s cancer peptides are intended for laboratory research and are not for diagnostic, therapeutic, or clinical use.
JPT’s Cancer Peptides
JPT offers a wide portfolio of high-quality cancer peptides engineered for robust and reproducible research in oncology. Our range mainly focuses on RGD and non-RGD variants such as iRGD, Cilengitide or Cecropin A and Bevacizumab. In addition, we offer reliable custom peptide synthesis to support diverse research applications in oncology, immunology, and vaccine development.
How to Choose the Right Cancer Peptide?
The right selection depends on the specific requirements of the experiment and the overall workflow. Key factors include peptide structure and sequence, target specificity, mechanism of action, and the intended application.
The following properties can help guide the selection of the most suitable option for your project:
- Target & Specificity: Selection depends on the ability to bind tumor-associated receptors (e.g., integrins) and ensure selective targeting of tumor cells.
- Mechanism of Action: Cancer targeting peptides can act through different pathways, including:
o Apoptosis induction
o Intracellular interference for example with DNA or protein synthesis
o Interaction with the tumor microenvironment + cell signaling
- Structure: Different structure influences stability and activity. Common formats include α-helical, β-sheet, cyclic, and random coil.
- Sequence: Sequences, such as RGD (Arg-Gly-Asp) help define targets and structure
- Physicochemical Properties: Features such as charge, hydrophobicity, and stability affect peptide behavior, bioavailability, and interaction with cell membranes.
- Application: The intended use, such as tumor targeting, imaging, drug delivery, or immune modulation, should align with the peptide’s functional properties.
JPT provides custom peptide synthesis services according to your research needs!
Main Types of Cancer Targeting Peptides
RGD Cancer Peptides
RGD cancer peptides are short amino acid sequences that contain the Arg-Gly-Asp (RGD) motif, which enables specific binding to integrin receptors on cell surfaces. These integrins, such as αvβ3 and αvβ5, are often overexpressed on tumor cells and in tumor blood vessels, especially during angiogenesis. By targeting these receptors, RGD peptides allow selective tumor targeting and delivery of therapeutic or imaging agents.
Depending on their design (mostly linear or cyclic), they can also enhance binding affinity, stability, and tumor penetration. This makes them widely used in oncological research for targeted drug delivery, imaging, and anti-angiogenic strategies.
Non-RGD Cancer Peptides
Non-RGD cancer peptides do not contain the Arg-Gly-Asp (RGD) motif and therefore do not rely on integrin binding for their activity. Instead, they interact with a wide range of alternative targets, such as tumor-specific receptors (e.g., hormone receptors), cell membranes, or intracellular pathways. This allows them to support diverse functions including tumor homing, cell penetration, direct tumor cell killing, and immune modulation.
Due to their structural and functional diversity, non-RGD variants can be tailored for different applications, including targeted therapy, drug delivery, and gene delivery. This often enables broader or complementary strategies compared to RGD-based targeting.
RGD vs non-RGD Peptides for Cancer
The following table compares RGD and non-RGD peptides to help researchers select the most suitable option for their specific research goals.
| Feature | RGD | Non-RGD |
| Primary Target | Integrin receptors (αvβ3, αvβ5, α5β1) on tumor cells and blood vessels | Diverse targets, including hormone receptors, non-RGD integrin sites, or intracellular targets |
| Mechanism | Receptor binding, endocytosis, inhibition of angiogenesis or tumor growth | Cell penetration, immune or hormonal modulation, or direct tumor cell killing |
| Structure | Linear or cyclic (show higher stability and affinity); contain the RGD motif | Diverse structures including linear, cyclic, α-helical, and β-sheet |
| Primary Use | Targeted drug delivery, anti-angiogenic therapy, molecular imaging (PET/SPECT) | Treatment of hormone-sensitive tumors, gene delivery, peptide-based therapies |
| Key Advantages | Small size enables deep tumor penetration; can combine targeting and penetration functions | Effective for hormone-driven tumors; CPPs allow receptor-independent delivery |
| Limitations | Short half-life; potential immunogenicity and rapid renal clearance | Risk of off-target effects (especially CPPs); complex synthesis for some analogs |
| Target Cancer Types | Solid integrin rich tumors with high angiogenesis, such as glioblastoma, melanoma, breast cancer | Hormone-dependent tumors, such as breast cancer and prostate cancer + broader tumor types |
| Common Examples | Cilengitide, iRGD, RGD-4C, CRGDSP, Cyclo(-RGDfK), GRGD-acid | Cecropin A, T3 Peptide, Bevacizumab, CooP, FREG, A6, Proapoptotic KLA, MOTS-c |
Can Peptides Cure Cancer?
Peptides do not directly cure cancer. However, they are widely researched and used to improve tumor diagnosis, imaging, and treatment through targeted and supportive therapeutic approaches.
Applications of Peptides for Cancer Treatment
Cancer peptides are used across a wide range of applications in oncology, from targeted therapy to diagnostics and direct tumor targeting:
1. Targeted Therapy: They enable selective delivery of therapeutic agents to tumor cells while minimizing effects on healthy tissue:
- Tumor Homing: Selectively target and accumulate in tumor tissue by binding to specific receptors or markers on tumor cells.
- Peptide-Drug Conjugates (PDCs): Some act as targeting ligands that deliver cytotoxic drugs directly to tumor sites, improving efficacy and reducing systemic toxicity.
- Radionuclide Therapy (PRRT): Variants such as octreotide deliver radioactive isotopes to specific tumor receptors, enabling localized radiation treatment (e.g., neuroendocrine tumors).
- Hormonal Therapy: Variants like leuprolide and goserelin regulate or block hormone signaling pathways involved in tumor growth, particularly in prostate and breast cancer.
2. Immunotherapy: Modulate immune responses against tumors.
- Peptide Cancer Vaccines: Derived from tumor-associated antigens, they can activate T-cells to recognize and eliminate tumor cells.
- Immune Modulation: Some enhance immune activity by supporting T-cell and natural killer cell function or by counteracting tumor-induced immune suppression.
3. Diagnosis & Imaging: Widely used for precise tumor detection and visualization.
- Fluorescent Imaging: Tumor-targeting peptides labeled with fluorescent dyes enable real-time visualization of tumor margins during surgery.
- Molecular Imaging: Radiolabeled versions allow sensitive detection of tumors and metastases using PET or CT imaging.
4. Direct Tumor Targeting: Some act directly on tumor cells to inhibit growth or induce cell death.
- Cell Penetrating Peptides: Cationic variants penetrate cell membranes, leading to rapid cell lysis.
- Intracellular Targeting: Some interfere with signaling pathways or proteins essential for tumor survival and proliferation.
Advantages of Cancer Targeting Peptides
- High specificity: Designed to bind tumor-associated receptors, enabling selective targeting
- Low toxicity: Composed of natural amino acids, often resulting in good safety and low immunogenicity
- Deep tissue penetration: Small size allows efficient penetration into solid tumors
- Easy modification: Can be readily optimized and modified
- Versatile mechanisms: Support targeting, drug delivery, apoptosis induction, angiogenesis inhibition, and immune activation
- Cost-effective production: Chemical synthesis is typically faster and more economical than biologic production
Why Choose JPT?
JPT Peptide Technologies brings over 20 years of experience in peptide design and manufacturing, supporting researchers across academia, biotechnology, and pharmaceutical industries worldwide. With a proven track record of delivering millions of high-quality products, JPT has established itself as a trusted partner for reliable and reproducible peptide solutions.
All our catalog products are provided with HPLC-MS analyses to confirm identity and ensure consistently high quality.
Benefits of JPT’s Peptides
- High-throughput synthesis for efficient and scalable production
- Manufactured in Germany under stringent quality standards
- Flexible ordering options, including bulk quantities and variable purities
- Freeze-dried aliquots available for enhanced stability and storage
- Proven expertise and dedicated scientific support
- Cost-effective and scalable solutions tailored to your needs
- Extensive modification options through custom peptide synthesis
Interested in Peptides and Cancer Research?
Interested in high-quality peptides or need assistance selecting the right product for your cancer research? Our reliable customer support team can support you with product information and custom peptide synthesis for modified or conjugated designs.
Please contact us or reach out to our scientific support team for personalized assistance. We are here to support your research and help you achieve reliable results.
Are you interested in other products? Check out our extensive peptide catalog for more options!